Accelerate FDA & Regulatory Clearance with Full-Service Medical Device Cybersecurity

The FDA generally expects evidence that cybersecurity risks are identified, controlled, and verified as part of device safety and effectiveness. A strong package typically includes device system scope, architecture and interfaces, threat modeling or equivalent analysis, a security risk assessment tied to impact, and security testing evidence. Reviewers also expect a plan to manage vulnerabilities and updates after launch, not just premarket claims.

A “cyber device” is a subset of devices that must meet specific cybersecurity information requirements under Section 524B in certain premarket submissions. In practice, you should be prepared to show documented cybersecurity processes and procedures, an SBOM, and a plan to monitor and address vulnerabilities over time. If your device includes software, connectivity, or third-party components, assess 524B applicability early to avoid late-stage submission gaps.

An SBOM is an inventory of software components and dependencies in your device system, including third-party and open-source components. FDA focuses on SBOMs because software supply chain vulnerabilities can affect safety and effectiveness and require fast impact analysis. A credible SBOM approach also explains how it will be generated, maintained, and used for monitoring and response across the lifecycle.

Penetration testing is often expected when a device has exposed interfaces, connectivity, or cybersecurity risks that could impact safety, effectiveness, or clinical operations. The goal is to demonstrate exploitability analysis and control effectiveness that matches your risk profile and device system scope. Strong evidence includes clear scope, methods summary, prioritized findings, remediation actions, and retest results when fixes are applied.

A cybersecurity deficiency means the reviewer could not verify one or more cybersecurity claims based on the evidence provided. The most effective responses map each deficiency question to specific artifacts, rationale, and test evidence that closes the gap with traceability. If needed, add targeted testing or updated documentation, then provide a clear retest summary tied to the original finding.

An SPDF is a set of secure development lifecycle processes intended to reduce the number and severity of vulnerabilities across design, development, release, and support. In practice, it includes repeatable activities like threat modeling, secure design requirements, dependency controls, security testing, and change control tied to risk decisions. You demonstrate an SPDF by showing consistent, traceable outputs and evidence of execution, not just a policy statement.

The FDA expects manufacturers to be able to receive, assess, and address vulnerabilities after launch as part of total product lifecycle security. A practical program includes intake and triage, risk assessment criteria, coordinated disclosure communications, update planning, and tracking to closure. Postmarket readiness also includes SBOM maintenance and monitoring so new vulnerabilities can be evaluated quickly.

Manufacturers commonly align cybersecurity work to risk management and software lifecycle standards, then add security engineering practices appropriate to the device system and environment. Frequently referenced standards include ISO 14971 (risk management), IEC 62304 (software lifecycle), IEC 81001-5-1 (health software security activities), and AAMI guidance such as TIR57 and TIR97. Many teams also reference NIST publications to inform security control selection and risk-based implementation.